TransMedics Group, Inc. — Director's Dealing 2022

Dec 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-09-02

Reporting Person: Provost Miriam (VP, Global Regulatory Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-02	Common Stock	M	2600	$3.22	Acquired	12038	Direct
2022-12-09	Common Stock	M	3977	$38.46	Acquired	16015	Direct
2022-12-09	Common Stock	S	3046	$59.00	Disposed	12969	Direct
2022-12-09	Common Stock	M	1149	$16.14	Acquired	14118	Direct
2022-12-09	Common Stock	S	567	$59.00	Disposed	13551	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-02	Stock Option (Right to Buy)	$3.22	M	2600	Disposed	2028-04-05	Common Stock (2600)	Direct
2022-12-09	Stock Option (Right to Buy)	$38.46	M	3977	Disposed	2031-02-24	Common Stock (3977)	Direct
2022-12-09	Stock Option (Right to Buy)	$16.14	M	1149	Disposed	2030-02-27	Common Stock (1149)	Direct

Footnotes

F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options.

F2: The option is fully vested.

F3: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.

F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020.